Ideas to Action:

Independent research for global prosperity

CGD Policy Blogs

 

FDA Approves RotaTeq

On Friday, Merck received FDA approval for its new oral rotavirus vaccine, RotaTeq, and will begin domestic distribution within a week. At a cost of $187.50 for the three-dose series, RotaTeq is one of the most expensive vaccines to date; by 2009, the company forecasts that the vaccine could bring in as much as $500 million in annual revenue.

According to the New York Times: